Table 2.

Most frequent treatment regimens from first-line to fourth-line chemotherapy in patients with metastatic colorectal cancer in Spain

Line	Regimen	n	%
First N = 873	FOLFOX-Bevacizumab	156	17.9
	FOLFOX	113	12.9
	CAPOX	101	11.6
	CAPOX-Bevacizumab	68	7.8
	FOLFOX-Panitumumab	67	7.7
	FOLFIRI-Bevacizumab	51	5.8
	FOLFIRI	47	5.4
Second N = 507	FOLFIRI-Bevacizumab	70	13.8
	FOLFIRI	59	11.6
	FOLFIRI-Aflibercept	57	11.2
	FOLFOX-Bevacizumab	35	6.9
	FOLFIRI-Cetuximab	31	6.1
	FOLFIRI-Panitumumab	29	5.7
	FOLFOX	29	5.7
Third N = 255	FOLFOX	26	11.1
	FOLFIRI	19	8.1
	Regorafenib	19	8.1
	FOLFOX-Bevacizumab	18	7.7
	Capecitabine-Bevacizumab	13	5.5
	FOLFIRI-Bevacizumab	13	5.5
	FOLFIRI-Cetuximab	13	5.5
Fourth N = 106	Regorafenib	14	13.2
	FOLFIRI-Bevacizumab	9	8.5
	Capecitabine	8	7.5
	FOLFOX	7	6.6
	Capecitabine-Bevacizumab	6	5.7
	FOLFIRI	6	5.7
	FOLFIRI-Cetuximab	6	5.7
	FOLFOX-Bevacizumab	6	5.7

CAPOX capecitabine/oxaliplatin, FOLFIRI 5-FU/leucovorin/irinotecan, FOLFOX 5-FU/leucovorin/oxaliplatin, n number of patients with the characteristic